Related by context. All words. (Click for frequent words.) 71 chemoradiotherapy 70 refractory ovarian cancer 70 interferon ribavirin 68 taxane chemotherapy 68 cisplatin chemotherapy 67 postoperative chemotherapy 67 docetaxel chemotherapy 67 platinum refractory 67 BEACOPP 67 doublet chemotherapy 67 Doxil ® 67 rituximab Rituxan 67 neoadjuvant therapy 67 debulking surgery 66 refractory SCLC 66 relapsed ovarian cancer 66 CHOP chemotherapy 66 Platinol ® cisplatin 66 concurrent chemoradiation 66 paclitaxel carboplatin 66 anthracycline taxane 65 clodronate 65 recurrent glioblastoma multiforme 65 GnRH agonist 65 fallopian tube carcinoma 65 mitoxantrone plus 65 biochemical relapse 65 chemoradiation therapy 65 alkylating agent 65 cytoreduction 65 ER CHOP 65 relapsed MM 65 operable breast cancer 64 chemotherapeutic regimens 64 #mg/m# [002] 64 Pemetrexed 64 metastatic malignant 64 adjuvant radiotherapy 64 irinotecan chemotherapy 64 IV NSCLC 64 mitoxantrone chemotherapy 64 mitoxantrone 64 Pegylated Interferon 64 chemotherapy cisplatin 64 androgen ablation 64 relapsed CLL 64 immunosuppressive regimen 64 Helicobacter pylori eradication 64 taxane therapy 64 Oxaliplatin 64 pegfilgrastim 64 lenalidomide Revlimid R 64 peritoneal cancer 64 metastatic renal cell carcinoma 64 DMARD therapy 64 colorectal cancer liver metastases 63 chemoradiation 63 haematologic 63 chemotherapy docetaxel 63 adjuvant cisplatin 63 preoperative chemotherapy 63 pegylated liposomal doxorubicin 63 gemcitabine cisplatin 63 nab paclitaxel 63 estramustine 63 gefitinib Iressa 63 oral clodronate 63 neoadjuvant chemotherapy 63 postoperative complication 63 Cisplatin 63 intravenous bisphosphonates 63 FOLFOX6 63 cytoreductive surgery 63 metastatic malignant melanoma 63 progression TTP 63 hematologic toxicity 63 parathyroidectomy 63 myeloablative 63 antiangiogenic therapy 63 fulvestrant 63 Imiquimod 63 mg/m2 dose 63 baseline LDH 63 unresectable tumors 63 metastatic GIST 63 adriamycin 63 locoregional recurrence 63 decitabine 62 mycophenolate mofetil 62 androgen deprivation 62 Mitomycin C 62 nadolol 62 β blockers 62 papillary renal cell carcinoma 62 5FU 62 epirubicin 62 trastuzumab Herceptin ® 62 postoperative mortality 62 metastatic bladder 62 adjuvant radiation 62 etoposide 62 severe neutropenia 62 intravenous diuretics 62 5-FU/LV 62 fluorouracil 62 LHRH analogues 62 weekly subcutaneous injections 62 EXJADE 62 surgical debulking 62 MCyR 62 resectable 62 erlotinib Tarceva 62 endometrial carcinoma 62 intravenous cyclophosphamide 62 PSA nadir 62 neoadjuvant 62 ABVD 62 antithymocyte globulin 62 postoperative morbidity 62 Toxicities 62 doxorubicin cyclophosphamide 62 Femara letrozole 62 flutamide 62 recurrent metastatic 62 gastrointestinal stromal tumor GIST 62 ethambutol 62 chemotherapy regimens 62 serous ovarian cancer 62 Paraplatin ® 62 localized renal 62 colorectal adenoma 62 ALA PDT 62 chemotherapy regimen 62 seminoma 62 pancreatic adenocarcinoma 62 APTIVUS r 62 paclitaxel Taxol R 62 abacavir Ziagen 62 Paraplatin ® carboplatin 62 antihypertensive therapy 62 deep venous thromboses 62 temozolomide Temodar 62 endometrial hyperplasia 62 CCyR 62 posttraumatic arthritis 62 thrombocytosis 62 cilengitide 62 hepatic metastases 62 tenecteplase 62 prednisone prednisolone 62 aromatase inhibitor therapy 61 idarubicin 61 chemos 61 nephrotoxic 61 TKI therapy 61 Neoadjuvant 61 antithrombotic therapy 61 resectable pancreatic cancer 61 paclitaxel chemotherapy 61 external beam radiotherapy 61 CIN3 61 docetaxel Taxotere 61 subtrochanteric 61 Natalizumab 61 urothelial cancer 61 LHRH receptor positive 61 perioperatively 61 cisplatin carboplatin 61 neutrophil counts 61 taxotere 61 radiotherapy RT 61 lichen planus 61 cyclophosphamide methotrexate 61 radioiodine therapy 61 FOLFIRINOX 61 thrombotic complications 61 hepatorenal syndrome 61 gemcitabine Gemzar 61 bevacizumab Avastin 61 invasive candidiasis 61 biliary tract cancer 61 antiretroviral naïve 61 Fludarabine 61 orchiectomy 61 mutated KRAS 61 recurrent glioblastoma 61 goserelin 61 anagrelide 61 methotrexate therapy 61 cisplatin 61 Leucovorin 61 corticosteroid dexamethasone 61 imatinib Gleevec 61 oral leukoplakia 61 fallopian tube cancers 61 symptomatic paroxysmal AF 61 tipranavir ritonavir 61 melphalan prednisone 61 GnRH agonists 61 detectable HCV RNA 61 urothelial bladder cancer 61 nonmetastatic prostate cancer 61 cystectomy 61 ritonavir boosted 61 conventional DMARDs 61 tyrosine kinase inhibitors TKIs 61 Vidaza azacitidine 61 tumor histology 61 HBeAg seroconversion 61 folinic acid 61 NMIBC 61 systemic corticosteroid 61 neutropenic 61 doxorubicin docetaxel 61 neoadjuvant treatment 61 cytogenetic responses 61 NATRECOR ® 61 paricalcitol 61 pT3 61 Aptivus ® 61 Cytoxan 61 cytotoxic therapy 61 stage IIIb 61 AGILECT R 61 liver resection 61 gastrointestinal stromal tumors GIST 61 radiochemotherapy 61 ribavirin RBV 61 carboplatin paclitaxel 61 TTF Therapy 61 HBeAg positive patients 61 hemorrhagic cystitis 61 KRAS mutant tumors 61 #Gy 61 HER2 overexpression 61 Mitoxantrone 61 Vincristine 61 TAXOTERE R 61 HSCT 61 electrical cardioversion 61 leukemia AML 61 Sanofi Aventis Taxotere 61 paclitaxel Taxol 61 5-fluorouracil/leucovorin 60 TMP SMX 60 Gemcitabine 60 refractory NSCLC 60 pCR 60 pegylated interferon alfa 60 resistant ovarian cancer 60 fluoropyrimidine 60 FOLFOX4 60 LPV r 60 Adjuvant chemotherapy 60 percutaneous drainage 60 peginterferon 60 TNF antagonist 60 severe exacerbations 60 malignant ascites 60 colorectal liver metastases 60 4mg/kg 60 adalimumab Humira 60 PegIFN RBV 60 Flu Cy 60 corifollitropin alfa 60 liposomal doxorubicin 60 strontium ranelate 60 ibandronate 60 cefuroxime 60 artery embolization 60 allogeneic HSCT 60 invasive ductal 60 lumbar disk herniation 60 durable remissions 60 metastatic RCC 60 temozolomide 60 symptomatic intracranial 60 gemtuzumab ozogamicin 60 DFMO 60 prostate carcinoma 60 GISTs 60 microwave hyperthermia 60 adalimumab 60 malignant pleural mesothelioma 60 Surgical resection 60 abacavir lamivudine 60 Retreatment 60 repigmentation 60 histologically confirmed 60 antiandrogen 60 elevated transaminases 60 ZACTIMA 60 antiepileptic medications 60 mitomycin C 60 EGFRIs 60 EGFR TKI 60 octreotide LAR 60 sarcomatoid 60 Tumors shrank 60 tamoxifen Nolvadex ® 60 complete cytogenetic response 60 atazanavir ritonavir 60 Peg IFN 60 RECIST criteria 60 androgen suppression therapy 60 histologic subtype 60 antiplatelet medication 60 pamidronate 60 mRCC 60 cisplatin gemcitabine 60 chlorambucil 60 photocoagulation 60 thrombocytopenic 60 TAXOTERE ® 60 FUSILEV enhances 60 palliative radiotherapy 60 femoral neck fracture 60 FASLODEX 60 hematopoietic cancers 60 PSADT 60 Chemoradiation 60 romiplostim 60 Radical prostatectomy 60 corticosteroid therapy 60 androgen suppression 60 cranial radiation 60 gemcitabine chemotherapy 60 Pegasys plus Copegus 60 Anthracycline 60 placebo dexamethasone 60 alefacept 60 IFN beta 60 letrozole Femara 60 immune thrombocytopenic purpura ITP 60 daily subcutaneous injections 60 allogeneic stem cell 60 eribulin mesylate 60 postoperative radiotherapy 60 breast carcinoma 60 serum calcium levels 60 CAELYX 60 deferoxamine 60 clinically localized prostate 60 liver metastasis 60 metastatic CRC 60 moderately emetogenic 60 immunosuppressive medications 60 gemcitabine carboplatin 60 tumor shrinkage 60 idraparinux 60 recurrent genital herpes 60 bendamustine 59 superficial bladder cancer 59 daunorubicin 59 epirubicin cisplatin 59 prostate cancer PCa 59 squamous cell carcinoma SCC 59 variceal hemorrhage 59 BARACLUDE ® 59 transaminase elevations 59 salmeterol fluticasone 59 node metastases 59 virological failure 59 TACE 59 certolizumab 59 rechallenge 59 carboplatin 59 HNSCC 59 Trastuzumab 59 uric acid lowering 59 thyrotoxicosis 59 CsA 59 anthracycline containing 59 paclitaxel Taxol ® 59 receiving VICTRELIS 59 mycophenolate 59 bacillus Calmette Guerin 59 ribavirin therapy 59 tumor necrosis 59 cinacalcet 59 hormonal therapies 59 taxane resistant 59 Thal Dex 59 verteporfin 59 heavily pretreated patients 59 leucopenia 59 VELCADE melphalan 59 topotecan 59 anthracycline chemotherapy 59 differentiated thyroid 59 recurrent VTE 59 response CCyR 59 oral rivaroxaban 59 postoperative infection 59 mycophenolic acid 59 protease inhibitor PI 59 bleomycin 59 administered subcutaneously 59 sustained virological response 59 drug eluting stent implantation 59 acute GvHD 59 FOLFIRI alone 59 standard chemotherapy regimen 59 lung resection 59 metastatic squamous cell carcinoma 59 postprocedure 59 ciclosporin 59 nodal metastasis 59 dacarbazine 59 sorafenib Nexavar 59 pyrazinamide 59 locoregional 59 MIRAPEX 59 dalteparin 59 injected subcutaneously 59 posttransplant 59 boosted protease inhibitor 59 adverse cytogenetics 59 PREZISTA r 59 AZT zidovudine Retrovir 59 Myelodysplastic Syndrome MDS 59 DAPT 59 Gliadel Wafer 59 neurocognitive outcomes 59 urothelial carcinoma 59 ulcerative colitis UC 59 anti angiogenic agents 59 Sutent sunitinib 59 thromboembolic disease 59 KRAS mutations occur 59 steroid dexamethasone 59 Doxorubicin 59 autologous SCT 59 vinorelbine 59 invasive fungal infection 59 serum potassium levels 59 non splenectomized 59 recurrent ovarian cancer 59 FOLFIRI 59 wound dehiscence 59 ARB telmisartan 59 sacral neuromodulation 59 EGFR expressing 59 stage IIIB IV 59 ototoxicity 59 anthracyclines taxanes 59 LHRH agonist 59 induce remission 59 metastatic neuroendocrine tumors 59 unresectable stage 59 pain palliation 59 genotypic resistance 59 cardiotoxic 59 basiliximab 59 antitumor effect 59 pancreatic resection 59 chemotherapy 59 basal cell skin 59 epirubicin cyclophosphamide 59 histologically proven 59 mucinous 59 Fluorouracil 59 isoproterenol 59 surgically resectable 59 EDSS scores 59 interferon alfa 2b 59 KRAS status 59 decompensated cirrhosis 59 Hypotension 59 refractory chronic myeloid 59 intra arterial chemotherapy 59 Irinotecan 59 Taxotere ® 59 MGd 59 intermittent dosing 59 rFVIIa 59 Taxotere docetaxel 59 PEG IFN 59 virologic failure 59 vinca alkaloid 59 methotrexate monotherapy 59 nonsmall cell lung cancer 59 refractory metastatic 59 Tarceva erlotinib 59 oblimersen 59 prospectively stratified 59 curative resection 59 #mg/m# [001] 59 stage IIIB 59 8mg/kg 59 Bevacizumab Avastin 59 candidemia 59 Decitabine 59 dacarbazine DTIC 59 infusional 59 Naive Patients 59 lymphocytosis 59 histological subtype 59 Dasatinib 59 immunomodulatory therapy 59 Gleevec imatinib 59 induced neuropathy 59 endocrine therapies 59 neurologic progression 59 farletuzumab 59 skeletal metastases 59 autoantibody positive 59 receiving highly emetogenic 59 tinidazole 59 amoxicillin clavulanate 59 Navelbine ® 59 locoregional disease 59 cytotoxic chemotherapy 59 intravitreal injections 59 Levodopa 59 colon resection 59 Fludara 59 bolus dose 59 urolithiasis 59 remission CR 59 transplantation HCT 59 retransplantation 59 systemic antifungal 59 postoperative infections 59 alkylating agents 59 remission induction 59 liver transplant recipients 58 refractory AML 58 patients undergoing CABG 58 liver biopsies 58 nonmelanoma skin cancers 58 achieved CCyR 58 papillary carcinoma 58 dose cohort 58 APTIVUS R 58 tacrolimus ointment 58 achieved sustained virologic 58 virological response 58 5 fluorouracil 58 abdominal hysterectomy 58 anterior uveitis 58 BoNTA 58 eflornithine 58 LHRH agonists 58 Oral corticosteroids 58 SUVmax 58 axillary dissection 58 partial remissions 58 Surgical excision 58 chronic GVHD 58 mg/m2/day 58 denileukin diftitox 58 Cetuximab 58 capecitabine Xeloda 58 reinfarction 58 dose cytarabine 58 Ribavirin causes 58 complete cytogenetic 58 patients evaluable 58 adjunctive placebo 58 nonmyeloablative 58 Platinol ® 58 Interferon beta 58 hemodilution 58 #mg/day [002] 58 5 Fluorouracil 58 Novantrone 58 pneumonectomy 58 intravenous morphine 58 Etoposide 58 nonmetastatic 58 radiation chemoradiation 58 rindopepimut 58 HoLEP 58 recurrent prostate cancer 58 ovulatory cycles 58 EBRT 58 imipenem 58 FOSRENOL ® 58 transarterial 58 % CI #.#-#.# [003] 58 vandetanib 58 oral Hycamtin 58 basal cell cancers 58 immunosuppressives 58 intracranial hemorrhage ICH 58 Gleevec resistant 58 sargramostim 58 mg kg dose 58 relapsing remitting MS RRMS 58 anastrazole 58 basal cell carcinoma BCC 58 androgen blockade 58 malignant neoplasm 58 ara C 58 epithelial ovarian cancer 58 cytotoxic therapies 58 thyroid carcinoma 58 perioperative morbidity 58 overt nephropathy 58 Angioedema 58 paclitaxel cisplatin 58 BEXXAR Therapeutic Regimen 58 Xelox 58 caspofungin 58 Neovascular Age Related Macular 58 intratumoral 58 somatostatin analogues 58 TURP 58 Taxol paclitaxel 58 Erlotinib 58 sunitinib 58 AA Amyloidosis 58 Hepatocellular Carcinoma HCC 58 Glioblastoma Multiforme GBM 58 glycated hemoglobin levels 58 recurrent NSCLC 58 ritonavir boosted lopinavir 58 bevacizumab Avastin ® 58 Platinol 58 recurrent GBM 58 non squamous NSCLC 58 bisphosphonate therapy 58 nilotinib 58 glycoprotein IIb IIIa inhibitor 58 lanthanum carbonate 58 cidofovir 58 azathioprine 58 achieved ACR# 58 severe hypersensitivity reactions 58 secondary hyperparathyroidism 58 Neulasta ® 58 glucocorticoid therapy 58 mycosis fungoides 58 leuprorelin 58 acute lymphoblastic 58 mesalamine granules 58 FXIII 58 cytogenetic response 58 dexamethasone Decadron 58 graft dysfunction 58 chemotherapeutic agent 58 #mg QD [001] 58 paclitaxel poliglumex 58 hemorrhagic complications 58 peginterferon alfa 2a #KD 58 chronic idiopathic thrombocytopenic purpura 58 Gemzar gemcitabine 58 beta blocker therapy 58 virologically 58 bony metastases 58 etanercept Enbrel 58 hepatocellular carcinomas 58 ductal breast cancer 58 calcineurin inhibitor 58 underwent surgical resection 58 FOLPI 58 Carboplatin 58 tumor recurrence 58 nonalcoholic steatohepatitis NASH 58 peritoneal carcinomatosis 58 cyclophosphamide 58 anemia neutropenia 58 ovarian suppression 58 Folfox 58 DMARD 58 nonoperative treatment 58 SCCHN 58 posttreatment 58 surgical revascularization 58 immune modulating 58 thalidomide Thalomid 58 Postoperatively 58 serum phosphate 58 resected pancreatic cancer 58 HIPEC 58 docetaxel 58 aromatase inhibitor AI 58 vincristine doxorubicin 58 CIMZIA TM certolizumab pegol 58 erlotinib Tarceva ® 58 metastatic colorectal carcinoma 58 interferon alfa 2a 58 severe hypoglycaemia 58 alpha interferons 58 vaginal hysterectomy 58 postoperative AF 58 metastatic lung cancer 58 chemotherapy radiotherapy 58 antiretroviral regimen 58 Proxinium TM 58 zidovudine lamivudine 58 baminercept 58 thrombolytic agents 58 ovarian carcinoma 58 aspirin clopidogrel 58 standard chemotherapy regimens 58 ACTEMRA TM 58 nicardipine 58 perioperative mortality 58 urinary bladder cancer 58 recurrent ovarian 58 virological suppression 58 galiximab 58 Alkeran 58 piperacillin tazobactam 58 pretransplant 58 Epirubicin 58 percutaneous vertebroplasty 58 BrachySil ™ 58 Insulin PH# 58 % CI #.#-#.# [007] 58 heavily pretreated 58 GIST tumors 58 castrate resistant 58 adenoma recurrence 58 bowel resection 58 hypertrophic scars 58 biologic DMARD 58 gastrointestinal stromal tumors GISTs 58 FOLFOX 58 intravesical therapy 58 tamoxifen therapy 58 HBeAg negative 58 stage IIIA 58 sunitinib malate 58 Xanafide 58 clomipramine 58 anthracycline therapy 58 interferon alfa 58 thromboprophylaxis 58 metastatic SCCHN 58 sulfasalazine 58 CK # administered 58 mTOR inhibitors 58 mg qd 58 rituximab Rituxan ® 58 HAART regimen 58 membranous nephropathy 58 pentoxifylline 58 orchidectomy 58 Partial Responses 58 refractory myeloma 58 intravesical 58 induced anemia 58 labetalol 58 CIMZIA TM 57 antiemetics 57 recurrent DVT 57 bronchogenic carcinoma 57 hip resurfacing arthroplasty 57 rituximab 57 percutaneous nephrolithotomy 57 neoadjuvant radiation 57 antimicrobial prophylaxis 57 underwent resection 57 antiestrogen therapy 57 deferiprone 57 H. pylori eradication 57 RBC transfusions 57 undetectable PSA 57 prostate cancer CRPC 57 graft occlusion 57 Venous thromboembolism 57 microtubule inhibitor 57 zoledronic acid Zometa 57 rash urticaria 57 CANCIDAS 57 systemic ALCL 57 Chronic Myelogenous Leukemia CML 57 Capecitabine 57 weekly intravenous infusions 57 dacarbazine chemotherapy 57 hepatectomy 57 Azathioprine 57 pulmonary artery banding 57 naïve HCV 57 interferon IFN 57 flecainide 57 AMEVIVE 57 autologous transplants 57 cilostazol 57 Ceplene/IL-2 57 lapatinib Tykerb 57 renal carcinoma 57 relapsed AML 57 glomerular filtration 57 metastatic gastric 57 oral antidiabetic medication 57 SUPPRELIN R LA 57 VTE prophylaxis 57 rt PA 57 % CI #.#-#.# [008] 57 esophagogastric 57 ICD shocks 57 trabectedin 57 refractory Hodgkin 57 tumors GIST 57 NATRECOR R 57 pyridostigmine 57 hepatic cirrhosis 57 fibrinolytic 57 peg interferon 57 gastrointestinal perforation 57 PASI scores 57 urethral stricture 57 ixabepilone 57 pulmonary dysfunction 57 EGFR tyrosine kinase inhibitors 57 mitomycin 57 cranial irradiation 57 Neupogen ® 57 ductal cancer 57 SLNB 57 ß blockers 57 rebleeding 57 lymphocytic leukemia 57 adjuvant therapy 57 Sezary syndrome 57 prostate TURP 57 hepatic fibrosis 57 stent implantation 57 ZOLINZA 57 cutaneous melanoma 57 peritumoral brain edema 57 antihormonal 57 imatinib therapy 57 postoperative pulmonary 57 intraperitoneal chemotherapy 57 dose cyclophosphamide 57 Velcade bortezomib 57 efavirenz EFV 57 neutropaenia 57 SCIg 57 thymectomy 57 Bisphosphonate 57 relapsed SCLC 57 Cimzia TM 57 Free Survival PFS 57 intravitreal injection 57 oral prednisone 57 timepoints 57 octreotide 57 bacterial prostatitis 57 acute gout flares 57 Patients Receiving 57 iron chelation therapy 57 epoprostenol 57 zalutumumab 57 anaplastic astrocytoma 57 Bacillus Calmette Guerin BCG 57 indolent lymphomas 57 gastric carcinoma 57 mcg albinterferon alfa 2b 57 B7 H3 57 myeloid metaplasia 57 adjuvant tamoxifen 57 tretinoin 57 cetuximab 57 atopic dermatitis AD 57 MAGE A3 ASCI 57 pulmonary exacerbation 57 papillary thyroid carcinoma 57 EGFR expressing mCRC 57 Sunitinib 57 dose clopidogrel 57 rFSH 57 FLT3 ITD 57 tipranavir r 57 suppressive therapy 57 levodopa therapy 57 hepatic resection 57 oral anticoagulation 57 radiofrequency ablation RFA 57 receptor tyrosine kinase inhibitor 57 nitrofurantoin 57 HER2 positive cancers 57 femoral neck fractures 57 epithelial ovarian 57 Gemzar ® 57 thymoma 57 Roche Herceptin 57 CYT# potent vascular disrupting 57 dose escalation phase 57 Procoralan 57 oral vancomycin 57 bypass grafting 57 amphotericin B 57 antibiotic prophylaxis 57 plus prednisone prednisolone 57 samalizumab 57 Lenalidomide 57 Adjunctive 57 aflibercept VEGF Trap 57 argatroban 57 prostate adenocarcinoma 57 palifermin 57 teriflunomide 57 posterior uveitis 57 analgesic medications 57 efalizumab 57 eribulin 57 Anti VEGF 57 temozolomide TMZ 57 trimethoprim sulfamethoxazole 57 CLL SLL 57 TroVax ® 57 beam radiotherapy 57 R0 resection 57 pegylated interferon alfa 2b 57 voriconazole 57 bevacizumab 57 secondary amenorrhea 57 refractory CML 57 aneurysm rupture 57 Alemtuzumab 57 plus gemcitabine 57 anticoagulation therapy 57 acute myeloid 57 MS relapses 57 pegylated interferon alpha 57 perioperative complications 57 inotropic 57 cisplatin resistant 57 cyclophosphamide doxorubicin vincristine 57 femoral shaft fracture 57 antiresorptive 57 gastric adenocarcinoma 57 saline placebo 57 bladder tumors 57 5 FU leucovorin 57 ICD implantation 57 cetuximab Erbitux R 57 B Cell Lymphoma 57 NRTI 57 plasma uric acid 57 tumor regressions 57 dose dexamethasone 57 chemotherapeutic drug 57 Cytarabine 57 long acting bronchodilator 57 stage chemoresistant ovarian 57 elevated serum creatinine 57 ancrod 57 proliferative retinopathy 57 CR CRu 57 #mg BID [001] 57 gastroesophageal junction 57 Peginterferon 57 ximelagatran 57 cutaneous squamous cell carcinoma 57 CA4P 57 peginterferon alfa 2a 57 NSTE ACS 57 portal vein thrombosis 57 PegIntron 57 Stage IIIb 57 N acetylcysteine 57 fondaparinux 57 invasive lobular 57 GLIADEL R Wafer 57 ischemic complications 57 vulvar intraepithelial neoplasia 57 Solid Tumours 57 Intravitreal 57 exemestane 57 ranibizumab Lucentis 57 endometrial biopsy 57 BRCA mutation carriers 57 busulfan 57 sulfadoxine pyrimethamine 57 interferon beta therapy 57 docetaxel prednisone 57 3TC lamivudine Epivir 57 anakinra 57 forodesine 57 Gonadotropin 57 Progressive Multifocal Leukoencephalopathy 57 fosamprenavir 57 needle aspiration 57 therapeutic regimens 57 Noxafil 57 adefovir 57 preoperative evaluation 57 Intravenous immunoglobulin 57 hepatic encephalopathy HE 57 unresectable HCC 57 immunosuppressive medication 57 hypofractionated 57 docetaxel Taxotere ® 57 undetectable HBV DNA 57 Dacogen decitabine 57 intra articular injection 57 non hodgkin lymphoma 57 fibrinolysis 57 testicular cancers 57 NRTI backbone 57 lumiliximab 57 hyperalgesia